About this medicine

Disulfiram supports abstinence through an alcohol deterrent effect. Treatment requires an agreed plan and appropriate support.

This is a voluntary abstinence aid, not a medicine to sober someone up or make continued drinking safer. An informed treatment agreement and practical support are central. It must not be secretly administered or used as punishment. People who may develop alcohol withdrawal need a separate medical plan before attempting to stop drinking.

What is this medicine used for?

UK guidance generally considers disulfiram when acamprosate or naltrexone are unsuitable, or an informed person prefers it and seeks abstinence.

The intended goal is maintained abstinence after withdrawal, rather than controlled drinking while taking the medicine. Treatment includes psychological and social support as well as tablets. A person’s preference matters, but clinicians must also establish that the alcohol restrictions and medical risks can be understood and followed.

Which warning signs need help?

Avoid alcohol during treatment and for up to 14 days afterwards, including alcohol in medicines, foods and toiletries. Chest pain, collapse or breathing difficulty after exposure requires emergency care: 999 in the UK, local emergency services elsewhere. Stop and seek urgent advice for jaundice or symptoms of liver injury.

Even products sold as low-alcohol or alcohol-free can be unsuitable if enough alcohol is present. Ask a pharmacist about medicines, foods, cosmetics and other possible exposures. Do not conduct a drinking challenge at home. Liver injury can be unpredictable: feeling unwell with fever or jaundice warrants stopping disulfiram and urgent medical advice.

How do I take it safely?

The label describes supervised loading then 100–200 mg daily. UK guidance also accepts starting 200 mg daily without loading. Initiation requires clinical assessment and at least 24 hours without alcohol.

The verified 200 mg tablet can be divided into equal 100 mg halves. The UK 24-hour minimum before starting differs from the shorter interval in some American labels. Do not restart after drinking or improvise a loading schedule without the treating service’s advice. The product label requires experienced specialist initiation.

What side effects should I know about?

Tiredness, nausea, bad breath and rash may occur. New numbness, visual changes, confusion or marked mood changes require review.

Nerve inflammation can cause pain or loss of sensation in the hands and feet; optic-nerve problems can affect vision. These are reasons for assessment, not effects to ignore until the next routine visit. Do not drive or use machinery if drowsy or tired. The leaflet advises stopping and contacting a doctor for allergic skin reactions.

Who needs extra care with this medicine?

The checked label excludes significant cardiac disease, previous stroke, hypertension, psychosis, severe personality disorder and suicidal risk. Kidney, liver, respiratory or seizure disorders need particular assessment.

These restrictions concern treatment safety, not a judgement about a person’s character or recovery prospects. Diabetes, thyroid disease and brain injury also enter the medical assessment. A different alcohol-treatment approach may be needed when disulfiram is unsuitable; exclusion from one medicine is not exclusion from support.

Can it affect my other medicines?

Warfarin, phenytoin, theophylline and certain benzodiazepines may have stronger effects. Metronidazole and other medicines can cause serious interactions. A pharmacist should check all medicines before treatment starts.

An interaction may increase another medicine’s effect even when no alcohol is consumed. Diazepam and chlordiazepoxide can become more sedating; anticoagulant or antiseizure treatment may need closer review. Tell the prescriber when medicines are started or stopped, including antibiotics and non-prescription products, and check liquid preparations for alcohol.

What check-ups will I need?

Check baseline liver and kidney tests and arrange regular follow-up. Agreed support with dosing can help adherence; ongoing monitoring considers physical health, benefit and alcohol exposure.

DHSC guidance recommends review at least fortnightly for the first two months, monthly for the next four, and at least six-monthly for longer treatment. Blood-test frequency depends on initial results and medical history. Consensual support with witnessed dosing can help adherence; this is not covert administration.

What about pregnancy, breastfeeding and age?

There is no paediatric indication. First-trimester use and breastfeeding are not advised; pregnancy needs specialist assessment.

The absence of a paediatric indication is not a dose-calculation problem to solve by scaling down an adult tablet. Older people may have more cardiac, liver or interaction risks. Pregnancy requires specialist alcohol-treatment support; uncertainty about disulfiram must not lead to unsupported abrupt withdrawal from alcohol when dependence is present.

What if I miss a dose or want to stop?

Skip a forgotten dose if more than 12 hours have passed; never double. Discuss stopping and avoid alcohol for two further weeks.

If alcohol has been consumed, contact the treating service before another dose. The two-week alcohol restriction remains important after the final tablet, including when treatment ends because of an adverse effect. Follow-up should also address relapse prevention and ongoing support, not just remove the prescription.

How does it work?

Disulfiram changes how the body breaks down alcohol. Alcohol is first converted into acetaldehyde, a harmful intermediate substance, which is normally broken down further by an enzyme called aldehyde dehydrogenase. An enzyme is a protein that helps a chemical reaction happen.

Disulfiram inhibits that enzyme, reducing its ability to process acetaldehyde. If alcohol is consumed, acetaldehyde can build up and cause warm, red skin, feeling sick, vomiting or a fall in blood pressure; severe reactions can affect the heart and breathing. This is the disulfiram–alcohol reaction, and anticipating it can support an agreed decision not to drink.

The effect on alcohol processing can persist after the last tablet. Disulfiram does not make alcohol leave the body faster or protect the brain and liver from alcohol’s harms. The pathway cannot be used to predict a safe amount of alcohol or a safe time to test the reaction.

How does it affect my body?

Alcohol exposure can cause flushing, headache, nausea and a racing heart. More severe reactions can affect breathing and circulation; deliberately testing the reaction is dangerous.

An alcohol reaction is unpredictable, not simply an unpleasant but harmless reminder. Flushing and vomiting can progress to low blood pressure, abnormal heart rhythm, seizures or collapse. Without alcohol, tiredness and other adverse effects can still occur. A person does not need to experience a reaction to show that treatment is working.

How does my body process it?

Absorption varies, followed by rapid metabolism. Most breakdown products leave through the kidneys.

Breakdown of the parent compound does not immediately restore the inhibited enzyme. This helps explain why missing a tablet or stopping treatment does not remove alcohol sensitivity. Clinical review and liver tests are more useful here than an invented target blood concentration or a self-calculated clearance time.

How do treatment options differ?

Disulfiram produces an alcohol reaction, unlike acamprosate or naltrexone. All belong within a wider recovery plan; none replaces medical treatment for dangerous acute alcohol withdrawal.

Acamprosate and naltrexone act differently and are usually considered first for relapse prevention. Choosing between them and disulfiram includes treatment goals, health conditions and patient preference. Psychological treatment, peer support and help with housing or relationships may remain important whichever medicine is selected.

A closer look at the science

It irreversibly inhibits aldehyde dehydrogenase. Other enzyme effects, including dopamine-beta-hydroxylase and drug-metabolising enzymes, help explain additional effects and interactions.

Its sulphur-containing disulfide chemistry differs from opioid-receptor blockers such as naltrexone. Enzyme inhibition, rather than an immediate sensation after swallowing, is the key therapeutic action. Because enzyme activity remains affected after dosing stops, the chemical structure or time since one tablet cannot be used to calculate a safe drinking interval.

How was this medicine developed?

Antabuse remains a historical cross-edition alias. This record verifies Brown & Burk’s generic 200 mg tablet.

Older terminology in labels should not dictate how people seeking help are described. Modern educational explanations distinguish alcohol dependence, withdrawal treatment and relapse prevention. The historical Antabuse name helps identify the subject, but it does not establish current UK branded supply or justify importing American tablet strengths and schedules.

Sources and References

  1. Disulfiram 200 mg tablets — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. UK clinical guidelines for alcohol treatment — chapter 10, pharmacological interventions

    Scope: DHSC clinical guidance for UK alcohol treatment; local prescribing arrangements remain nation/service specific.

  3. Disulfiram 200 mg tablets — patient leaflet, sections 1–4 and 6

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. NHS: alcohol-use disorder

    Scope: England (NHS patient information; not a uniform UK referral pathway).

  5. Disulfiram: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology; Indications and Usage; Warnings: The Disulfiram-Alcohol Reaction. This does not establish UK product authorisation or prescribing..

  6. Incorporating Alcohol Pharmacotherapies Into Medical Practice: Chapter 3—Disulfiram — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Pharmacology: Aversive treatment. This does not establish UK product authorisation or prescribing..

  7. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top